Latham & Watkins LLP represented Terns Pharmaceuticals in the offering and Davis Polk advised the underwriters involved. Terns Pharmaceuticals, Inc. (Nasdaq: TERN), a clinical-stage biopharmaceutical company...
Terns Pharmaceuticals’ $86 Million Common Stock Offering
Prometheus Biosciences’ $500 Million Shares Offering
Wilson Sonsini and Latham & Watkins advised Prometheus Biosciences on the deal, while Davis Polk & Wardwell advised the representatives of the several underwriters. Prometheus Biosciences,...
Shoals Technologies Group’s $665 Million Stock Offering
Kirkland & Ellis advised Shoals Technologies Group, while Davis Polk advised the joint book-running managers and representatives of the underwriters in the offering. Shoals Technologies Group,...
FREYR Battery’s $264.5 Million Debut Public Share Offering
Davis Polk advised the underwriters in the offering. FREYR Battery announced the $264.5 million debut registered equity offering of 23,000,000 of its ordinary shares, which includes the full...
Prime Medicine’s $175 Million IPO
Wilson Sonsini and Honigman advised Prime Medicine on the deal, while Davis Polk advised the joint book-running managers. Prime Medicine, Inc., a biotechnology company committed to...
Gamida Cell’s $20 Million Shares Offering
Davis Polk advised the representative of the underwriters in the offering. Gamida Cell Ltd. announced the $20 million SEC-registered follow-on offering of 12,905,000 ordinary shares. The ordinary shares...
Alignment Healthcare’s $131.5 Million Secondary Offering
Paul, Weiss advised Alignment Healthcare, while Davis Polk advised the underwriter, J.P. Morgan Securities LLC, in the offering. Alignment Healthcare executed its SEC-registered secondary offering of 9,000,000...
Oak Street Health’s $180.3 Million Shares Offering
Davis Polk advised the joint book-running managers in the offering. Oak Street Health, Inc. announced the $180.3 million secondary offering of 7,000,000 million shares of common stock...
Terns Pharmaceuticals’ $65 Million Common Stock Offering
Latham & Watkins represented Terns Pharmaceuticals in the offering, while Davis Polk & Wardwell represented the underwriters. Terns Pharmaceuticals, Inc. (Nasdaq: TERN) has agreed to sell, by...
Bloom Energy’s $338 Million Shares Offering
Latham & Watkins represented Bloom Energy in the transaction, while Davis Polk advised the underwriters. Bloom Energy Corporation (NYSE: BE), the developer of a solid-oxide platform for...
Arrival’s $300 Million At-The-Market Offering
Davis Polk advised Barclays Capital, the manager, in the offering. Arrival executed a SEC-registered at-the-market offering of its ordinary shares for up to an aggregate offering price of...
RxSight’s $50 Million At-The-Market Offering
Davis Polk advised the sales agent in the offering. RxSight, Inc. announced its shares of common stock for up to an aggregate amount of $50 million....